Slide 1: An Innovative Biotech with a Robust R&D Engine
An Innovative Biotech with a Robust R&D Engine Developing First-in-Class and Best-In-Class Redefining the Anterior Segment with Multi-Kinase Inhibition Ophthalmic Drugs Dr. Mah Content Date Etc partners@cloudbreakpharma.com April 8, 2026 Partners@CloudbreakPharma.com Confidential | 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements regarding the future performance, plans and prospects of Cloudbreak Pharma, Inc. (with effect from 3 July 2025, shares listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “HKEX”)). These statements
Slide 3: Cloudbreak Pharma (HKEX: 2592)
Cloudbreak Pharma (HKEX: 2592) Our lead platform technology, Multi-Kinase Inhibitors CBT-001 and CBT-004 may become the first and only (MKIs), is uniquely suitable for fibrovascular ocular FDA-approved disease modifying drug therapies for these high-value conditions surface pathologies and de-risked
Slide 4: Leadership team with extensive industry and scientific expertise
Leadership team with extensive industry and scientific expertise Founder and CEO Scientific Team and Advisors Jinsong Ni, PhD Founder and Chief Executive Officer 30+ years of experience Expertise in discovery, development, clinical trials and product registration Van Son Dinh, MBA Rong Yang, PhD Abu
Slide 5: Cloudbreak Pharma is focused on key technologies
Cloudbreak Pharma is focused on key technologies: Commercial Pre- Technology Drug Candidate Indication Patent Status Phase 1 Phase 2 Phase 3 Status Availability clinical Granted US, EU, China, JPN, AUS, Pterygium Global (Ex. Brazil, CDN, S. Korea, Mexico, HK, Results of first MRCT CBT-001 (hyperemia
Slide 6: Pterygium and Pinguecula are caused by abnormal fibro-vascular growth
Pterygium and Pinguecula are caused by abnormal fibro-vascular growth of a lesion on the surface of the eye Normal course of the disease increases redness and lesion growth. Confidential | 6
Slide 7: Multi-kinase inhibitors are designed to address the root cause of these diseases
Multi-kinase inhibitors are designed to address the root cause of these diseases, and not just the symptoms Beyond Anti-VEGF: Single-target drugs fail due to pathway redundancy. Mechanism of Action: Simultaneous inhibition of multiple Receptor Tyrosine Kinases (RTKs). MKIs are the only class that ca
Slide 8: Pterygium overview
Pterygium overview A Disease impacting 15M people in the U.S. and with no FDA approved drug therapy Pterygium is a triangular fibrovascular growth on the cornea, connected to the conjunctiva. It is commonly caused by UV exposure and can lead to redness, irritation, and vision problems1. People impac
Slide 9: Today, palliative treatment is all doctors can offer
Today, palliative treatment is all doctors can offer, short of surgery for pterygium1 Non-Surgical Management Lubricants / Symptomatic relief only Vasoconstrictors / No Disease Modification Steroids / NSAIDs The Reality: Patient Diagnosis The majority of patients and doctors are less than satisfied
Slide 10: CBT-001 for Pterygium: Phase 2 clinical results
CBT-001 for Pterygium: Phase 2 clinical results demonstrate disease-modifying potential1 A representative eye treated with CBT-001 (A113) Day 1 p<0.001 10% Corneal Lesion Length Reduction in 4 Weeks (p<0.014) Week 4 1. Clinical study report for NCT03049852 on file Confidential | 10
Slide 11: CBT-001
CBT-001 Potential first approved drug treatment for pterygium, in late-stage clinical development for the reduction of hyperemia, bothersome symptoms, and stabilization or reduction of lesion size Potential Advantages On-going phase 3 MRCT • Phase 3 MRCT is a multicenter, double-masked, randomized,
Slide 12: Pinguecula
Pinguecula A disease impacting almost half of all adults above age 70 in the US and with no FDA approved drug therapy 1 Pinguecula is characterized as a round, yellowish, elevated growth that develops on the conjunctiva adjacent to the cornea which is prone to inflammation and vascularization. It is
Slide 13: CBT-004: Phase 2 clinical results demonstrate impressive efficacy
CBT-004: Phase 2 clinical results demonstrate impressive efficacy1 Day 1 Day 7 Day 28 Representative subject dosed with higher-dose CBT-004 1. Results from phase 2 study (NCT04884256) wherein CBT-004 met its clinical efficacy endpoints. Confidential | 13
Slide 14: CBT-004: Vascularity changes maintained up to weeks
CBT-004: Vascularity changes maintained up to 4 weeks as assessed from ocular images Vascularity change D28 vs D1 Vascularity change D56 vs D1 (28 days post-treatment) 80 80 70 60 60 Percent total Percent total 50 40 40 30 20 20 10 0 0 Veh 0.05% Lower Dose CBT-004 0.075% Higher Dose CBT-004 Veh Lowe
Slide 15: CBT-004 in phase 2 trial
CBT-004 in phase 2 trial Vascularity substantially reduced and the lesion (circle) became thinner and smoother at D28 Day 1 Day 28 Confidential | 15
Slide 16: Positive output from FDA end of phase 2 meeting
Positive output from FDA end of phase 2 meeting • Phase 3 primary efficacy endpoints will include conjunctival hyperemia as well as the key symptom of “foreign body sensation” • Both were statistically significant findings in the Phase 2 study with the dose included in the Phase 3 study • This would
Slide 17: CBT-004
CBT-004 An MKI eye drop designed to address the vascularization and inflammation of the pinguecula lesion Potential first FDA approved drug treatment for pinguecula, entering Phase 3 development for the reduction of hyperemia and bothersome symptoms caused by the lesion Potential Advantages Developm
Slide 18: Pterygium and pinguecula represent new drug category creation opportunities
Examples of Tactics Employed Pterygium and pinguecula represent new drug category creation opportunities Launched in 2003 as the first prescription dry eye product into a market that had previously been treated with OTC ocular lubricants Professional Congress Disease modifying rather than purely sho
Slide 19: Cloudbreak Pharma
Cloudbreak Pharma Q3 2026 Q4 2026 Q1 2027 Q4 2027 CBT-001 CBT-199 CBT-004 CBT-001 Top-line 12- Potential Phase Initiation of 90-Day results month results 2 results for Phase 3 from second from first program (and presbyopia in Phase 3 study confirmatory) USA/China Phase 3 study for for pterygium pter
Slide 20: Broad intellectual property portfolio
Broad intellectual property portfolio Key methods and 70+ Global Patents Issued formulation claims covered with multiple patents through 2036 and beyond 160+ Global Applications Pending Confidential | 20
Slide 21: Multiple commercialization partners
Multiple commercialization partners1 Potential long-term income stream Santen (4536.T) Grand Pharma (00512.HK) A global pharmaceutical company focusing on global R&D, An international pharmaceutical company with a strong manufacturing, and sales and marketing of eyecare products, marketing and sales
Slide 22: The Investment Ask
The Investment Ask $25 million equity investment will be The reduction in time increases the projects used to speed enrollment and reduce by value today to potential partners and reduces time to $100 million in potential six months the timeline for NDA’s for both regulatory milestones CBT-001 and CB
Slide 23: Cloudbreak Pharma (HKEX: 2592)
Cloudbreak Pharma (HKEX: 2592) CBT-001 and CBT-004 may become the first and only Our lead platform technology, Multi-Kinase Inhibitors FDA-approved disease modifying drug therapies for (MKIs), is uniquely suitable for fibrovascular ocular these high-value conditions surface pathologies and de-risked